OR WAIT null SECS
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
In this video, Allen C. Gao, MD, PhD, discusses the possibility of re-emerged PARP inhibitor resistant prostate cancer and what future studies should do to continue developing treatments. Gao was the senior author on the study, “Resistance to olaparib is dependent on re-emergence from G2/M arrested senescence,” which was presented at the 2021 AUA Annual Meeting.
Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.